Jim Cramer Says He Was Wrong for Selling Johnson & Johnson for the Charitable Trust

Group 1 - Johnson & Johnson has transitioned to a pure play in pharmaceuticals by spinning off its orthopedics division, which is considered a commoditized business [1] - The pharmaceutical segment of Johnson & Johnson is highlighted for having some of the best drugs in development, benefiting from the absence of the orthopedics business [1] - The company faces ongoing lawsuits related to its talc products, but these are viewed as less impactful on the stock's performance due to the company's strategy of fighting individual claims [1] Group 2 - Johnson & Johnson develops and sells a range of healthcare products, including pharmaceuticals and medical technologies, with a focus on areas such as immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2]